References
- Shamseddeen H Getty JZ Hamdallah IN Ali MR Epidemiology and economic impact of obesity and type 2 diabetes Surg Clin North Am 2011 91 6 1163 1172 vii 22054146
- Donner T Munoz M Update on insulin therapy for type 2 diabetes J Clin Endocrinol Metab 3 22 2012
- Fu AZ Qiu Y Radican L Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes Curr Med Res Opin 2009 25 6 1413 1420 19422281
- [No authors listed] Berberine Altern Med Rev 2000 5 2 175 177 10767672
- Vuddanda PR Chakraborty S Singh S Berberine: a potential phytochemical with multispectrum therapeutic activities Expert Opin Investig Drugs 2010 19 10 1297 1307
- Kong W Wei J Abidi P Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat Med 2004 10 12 1344 1351 15531889
- Hu Y Davies GE Berberine inhibits adipogenesis in high-fat diet-induced obesity mice Fitoterapia 2010 81 5 358 366 19861153
- Kong WJ Wei J Zuo ZY Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 2008 57 8 1029 1037 18640378
- Cameron J Ranheim T Kulseth MA Leren TP Berge KE Berberine decreases PCSK9 expression in HepG2 cells Atherosclerosis 2008 201 2 266 273 18355829
- Affuso F Ruvolo A Micillo F Saccà L Fazio S Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study Nutr Metab Cardiovasc Dis 2010 20 9 656 661 19699071
- Klimek M Wang S Ogunkanmi A Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia P T 2009 34 6 313 327 19572049
- Gordon RY Cooperman T Obermeyer W Becker DJ Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010 170 19 1722 1727 20975018
- Lin YL Wang TH Lee MH Su NW Biologically active components and nutraceuticals in the Monascus-fermented rice: a review Appl Microbiol Biotechnol 2008 77 5 965 973 18038131
- Yin J Xing H Ye J Efficacy of berberine in patients with type 2 diabetes mellitus Metabolism 2008 57 5 712 717 18442638
- Zhang H Wei J Xue R Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression Metabolism 2010 59 2 285 292 19800084
- Yin J Zhang H Ye J Traditional Chinese medicine in treatment of metabolic syndrome Endocr Metab Immune Disord Drug Targets 2008 8 2 99 111 18537696
- Chen W Miao YQ Fan DJ Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats AAPS Pharm Sci Tech 2011 12 2 705 711
- Pan GY Wang GJ Liu XD Fawcett JP Xie YY The involvement of P-glycoprotein in berberine absorption Pharmacol Toxicol 2002 91 4 193 197 12530470
- Tsai PL Tsai TH Hepatobiliary excretion of berberine Drug Metab Dispos 2004 32 4 405 412 15039293
- Chae HW Kim IW Jin HE Kim DD Chung SJ Shim CK Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine Arch Pharm Res 2008 31 1 103 110 18277615
- Zhou S Lim LY Chowbay B Herbal modulation of P-glycoprotein Drug Metab Rev 2004 36 1 57 104 15072439
- Paquot N Scheen AJ Which HbA1c and lipid targets in patients with type 2 diabetes? Rev Med Liege 2012 67 2 98 103 French 22482240
- Porte DJr Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications Diabetes Metab Res Rev 2001 17 3 181 188 11424231
- Liu L Yu YL Yang JS Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study Naunyn Schmiedebergs Arch Pharmacol 2010 381 4 371 381 20229011
- Zhang BJ Xu D Guo Y Ping J Chen LB Wang H Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors Clin Exp Pharmacol Physiol 2008 35 3 303 309 17973934